<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148131">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171989</url>
  </required_header>
  <id_info>
    <org_study_id>113978</org_study_id>
    <nct_id>NCT01171989</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose</brief_title>
  <official_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The current trial will evaluate the safety and immunogenicity of GSK Biologicals'
      GSK2202083A vaccine when administered as a booster dose following priming in the first year
      of life with the same vaccine.

      This protocol posting deals with objectives &amp; outcome measures of the booster phase. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT number = NCT00970307).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccine in terms of antibody concentrations/titres</measure>
    <time_frame>One month after the booster dose (Month1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccine in terms of antibody concentrations/titres</measure>
    <time_frame>One month after the booster dose (Month 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of antibodies to the study vaccine antigens</measure>
    <time_frame>Before the booster dose (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local and general symptoms</measure>
    <time_frame>During the 8-day (Day 0-7) follow-up period following the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>During the 31-day (Day 0-30) follow-up period following the booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>After the booster dose of the study vaccine up to the study end (Month 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <condition>Acellular Pertussis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK2202083A vaccine at Visit 1 and Synflorix™ at Visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Infanrix hexa™ co-administered with Menjugate™ at Visit 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Infanrix hexa™ co-administered with NeisVac-C™ at Visit 1 and Synflorix™ at Visit 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2202083A vaccine</intervention_name>
    <description>Intramuscular, one dose.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa™</intervention_name>
    <description>Intramuscular, one dose.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menjugate™</intervention_name>
    <description>Intramuscular, one dose.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C™</intervention_name>
    <description>Intramuscular, one dose.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix™</intervention_name>
    <description>Intramuscular, one dose.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that parent(s)/ legally acceptable
             representative(s) can and will comply with the requirements of the protocol.

          -  Subjects who have completed the full three-dose primary vaccination course according
             to their group allocation in the primary study DTPa-HBV-IPV=Hib-MenC-TT-002 (112157).

          -  A male or female between, and including, 12 and 18 months of age at the time of
             booster vaccination.

          -  Written informed consent obtained from the parent(s)/ legally acceptable
             representative(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the dose of study vaccine, or planned use during the study
             period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the booster vaccination.

          -  Planned administration/administration of immunoglobulins and/or any blood products
             within three months before the booster dose, or during the study period.

          -  Planned administration/administration of any vaccine not foreseen by the study
             protocol during the period starting 30 days before and ending 30 days after the
             booster dose.

          -  Participation in another clinical study since the primary study
             DTPa-HBV-IPV/Hib-MenC-TT-002 in which the subject has been or will be exposed to an
             investigational or a non-investigational product.

          -  Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib,
             pneumococcal and MenC vaccination or disease since the conclusion visit of study
             DTPa-HBV-IPV/Hib-MenC-TT-002.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  The following adverse event having occurred after previous administration of DTP
             vaccine:

               -  Encephalopathy.

               -  Temperature of &gt;= 40.5°C (rectal temperature) within 48 hours of vaccination,
                  not due to another identifiable cause.

               -  Collapse or shock-like state within 48 hours of vaccination.

               -  Persistent, inconsolable crying occurring within 48 hours of vaccination and
                  lasting &gt;= 3 hours.

               -  Seizures with or without fever occurring within 3 days of vaccination.

        The following condition is temporary or self-limiting, and a subject may be vaccinated
        once the condition has resolved if no other exclusion criteria is met:

        • Acute disease and/or fever at the time of enrolment.

          -  Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting, or ≥
             38.0°C on rectal setting.

          -  Subjects with a minor illness without fever may be enrolled at the discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-422</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Pediatr Infect Dis J. 2013 Jul;32(7):777-85. doi: 10.1097/INF.0b013e31828d6b20.</citation>
    <PMID>23838777</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 22, 2016</lastchanged_date>
  <firstreceived_date>July 27, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>December 23, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>booster vaccination</keyword>
  <keyword>combined vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113978</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
